Cantor Fitzgerald reiterated their overweight rating on shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) in a research note issued to investors on Wednesday, May 10th. The brokerage currently has a $32.00 target price on the biopharmaceutical company’s stock.
Other research analysts have also recently issued reports about the stock. Jefferies Group LLC reissued a buy rating and set a $19.00 price objective (down from $22.00) on shares of Bellicum Pharmaceuticals in a report on Tuesday, March 14th. Zacks Investment Research raised shares of Bellicum Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, January 17th. Finally, Wells Fargo & Company started coverage on shares of Bellicum Pharmaceuticals in a report on Wednesday, March 8th. They set an outperform rating and a $29.50 price objective for the company. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $27.79.
Bellicum Pharmaceuticals (NASDAQ:BLCM) traded up 1.35% on Wednesday, hitting $10.48. 539,499 shares of the stock were exchanged. The company has a 50-day moving average of $12.04 and a 200-day moving average of $13.33. The stock’s market cap is $346.92 million. Bellicum Pharmaceuticals has a 12 month low of $9.71 and a 12 month high of $23.11.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by $0.10. The firm had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $0.09 million. Bellicum Pharmaceuticals had a negative return on equity of 63.42% and a negative net margin of 17,957.31%. The firm’s quarterly revenue was up 39.1% on a year-over-year basis. During the same period last year, the firm posted ($0.56) earnings per share. On average, equities analysts predict that Bellicum Pharmaceuticals will post ($2.84) EPS for the current year.
In other Bellicum Pharmaceuticals news, CFO Alan A. Musso sold 6,311 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $12.24, for a total value of $77,246.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Bros. Advisors Lp Baker purchased 166,666 shares of the company’s stock in a transaction on Friday, March 24th. The stock was purchased at an average price of $12.00 per share, with a total value of $1,999,992.00. The disclosure for this purchase can be found here. Insiders own 23.30% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. TLP Group LLC purchased a new position in Bellicum Pharmaceuticals during the third quarter worth $111,000. Knott David M purchased a new position in Bellicum Pharmaceuticals during the first quarter worth $131,000. Wells Fargo & Company MN raised its position in Bellicum Pharmaceuticals by 161.9% in the third quarter. Wells Fargo & Company MN now owns 11,525 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 7,125 shares during the last quarter. Eagle Ridge Investment Management purchased a new position in Bellicum Pharmaceuticals during the first quarter worth $144,000. Finally, American International Group Inc. raised its position in shares of Bellicum Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 852 shares in the last quarter. Institutional investors and hedge funds own 65.14% of the company’s stock.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
What are top analysts saying about Bellicum Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bellicum Pharmaceuticals Inc. and related companies.